1606 Corp. Announces Strategic Investment in Adnexus Biotechnologies

SEATTLE, WA / ACCESSWIRE / September 17, 2024 – 1606 Corp. (OTC PINK:CBDW) has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc., a company specializing in AI-driven drug discovery and infectious disease research.

This investment underscores 1606 Corp.'s dedication to enhancing its technological capabilities within the AI sector. By integrating Adnexus's AI research, 1606 Corp. aims to make significant impacts in healthcare and biotechnology.

Adnexus operates SUTRA, an advanced AI platform identifying biomarkers for infectious and neurological diseases. The platform has developed effective monoclonal antibodies and houses extensive viral and molecular data.

Both companies express enthusiasm about the collaboration, predicting significant advancements and enhanced shareholder value. The deal is subject to standard due diligence and conditions in the LOI.